Related by context. All words. (Click for frequent words.) 83 pivotal Phase III 82 randomized Phase 78 Phase III clinical 76 Phase 2b clinical 74 placebo controlled Phase 74 Phase 2a clinical 73 Phase 2b 73 Phase III 73 Phase IIb 72 Phase III pivotal 72 Phase 2a 72 Phase 2b study 72 Phase 2b trial 72 Phase IIb clinical 72 Phase 1b 71 multicenter Phase 71 dose escalation trial 71 Phase Ib 70 phase IIb clinical 69 Phase 69 Phase IIa clinical 69 Phase 1b clinical 69 randomized controlled Phase 69 phase IIb 68 Phase III clinical trials 68 Phase IIa 68 phase IIa clinical 67 Phase IIb trial 67 Phase IIa trial 67 registrational trial 67 Phase 2a trial 67 dose escalation Phase 67 SUCCEED trial 67 Phase 1b trial 66 phase 2a 66 confirmatory Phase 3 66 phase IIa 66 Phase IIIb 66 registrational 66 LUX Lung 66 Phase IIb trials 66 Phase Ib clinical 65 Phase II 65 Phase III randomized 65 phase Ib 65 confirmatory Phase III 65 Phase III trials 65 initiate Phase 65 dose escalation study 64 oral ridaforolimus 64 Phase Ib II 64 label dose escalation 64 multiple ascending dose 64 Pivotal Phase 64 placebo controlled Phase III 64 dose escalation clinical 64 dose escalation 63 Phase 1a 63 clinical trial 63 randomized placebo controlled 63 multicenter Phase II 63 APPRAISE 63 Dacogen injection 63 ongoing Phase 1b 63 Phase IIIb clinical 63 randomized Phase III 63 PRE SURGE 63 Initiated Phase 63 randomized double 63 placebo controlled 62 Phase Ib study 62 Randomized Phase 62 randomized Phase 2b 62 label multicenter Phase 62 Phase 2b randomized 62 Phase Ia 62 multicenter randomized Phase 62 APEX PD 62 PRECiSE 62 Special Protocol Assessment 62 randomized controlled 62 double blind placebo 62 PDX pralatrexate 61 Phase IIB 61 multicenter phase 61 dose cohorts 61 glufosfamide 61 Phase Ib clinical trials 61 relapsed refractory multiple myeloma 61 oral deforolimus 61 Zerenex 61 sapacitabine 61 HCV SPRINT 61 Phase #b/#a clinical 61 PRX # 61 Phase #b/#a 61 COMFORT II 61 randomized multicenter 61 blind randomized placebo 60 BRIM3 60 Phase IIb clinical trials 60 Phase III Pivotal 60 PROPEL trial 60 label multicenter 60 hormone refractory prostate cancer 60 multicenter Phase III 60 ofatumumab 60 dirucotide 60 phase IIb trial 60 masked placebo controlled 60 Cloretazine R VNP#M 60 Investigational Device Exemption IDE 60 GALNS 60 NO# [002] 60 Initiate Phase 60 alvespimycin 60 HGS ETR1 60 placebo controlled randomized 60 viral kinetic 60 Phase IIa trials 60 BRIM2 60 randomized Phase IIb 60 obatoclax 60 ADVANCE PD 60 dose cohort 60 treatment naive genotype 60 Amigal 60 Phase 2b clinical trials 59 lorcaserin Phase 59 investigational compound 59 EOquin TM 59 lintuzumab 59 forodesine 59 rALLy clinical trial 59 Marqibo 59 FOLOTYN ® 59 double blinded placebo 59 Phase 2b kidney transplant 59 European Sepsis Trial 59 ANCHOR trial 59 RE SURGE 59 multicenter randomized double 59 Amrubicin 59 phase IIb study 59 axitinib 59 placebo controlled clinical 59 RDEA# 59 investigational pan BCR 59 celgosivir 59 voreloxin 59 ILLUMINATE 59 FOLOTYN 59 Phase III placebo controlled 59 IMPACT IMmunotherapy 59 blind placebo controlled 59 MOZOBIL 58 HER2 positive metastatic breast 58 DURATION 58 PEG PAL 58 multicenter randomized placebo controlled 58 ELACYT 58 investigational drug 58 MAA submission 58 Phase #/#a 58 Phase 1b dose escalation 58 multicenter 58 multicenter clinical 58 ganetespib 58 EOquin 58 metastatic hormone refractory 58 unblinded 58 Phase 1a clinical 58 TELCYTA 58 PFO migraine 58 Phase III randomized controlled 58 Fast Tracked Phase 58 pharmacokinetic 58 IIa trial 58 phase Ib clinical 58 docetaxel Taxotere R 58 ZYBRESTAT 58 comparing alemtuzumab 58 phase IIb III 58 relapsed multiple myeloma 58 pegloticase 58 phase IIIb 58 Omigard 58 fidaxomicin Phase 58 Pivotal Trial 58 AP# [003] 58 lintuzumab SGN 58 EFAPROXYN 58 CRMD# 58 Pivotal Phase III 58 IMC A# 58 MEND CABG II 58 nab paclitaxel 58 AEG# 58 TMC# C# 58 AZX# Phase 58 SinuNase TM 58 ZYBRESTAT fosbretabulin 58 prospective randomized 58 Zenvia Phase III 58 pharmacokinetic PK study 58 dosing cohorts 58 Sorafenib HCC Assessment 57 ThermoDox ® 57 peginesatide 57 deforolimus 57 IMGN# 57 perifosine 57 Phase IIb III 57 Phase III HEAT 57 ascending dose 57 Phase IIa clinical trials 57 blind randomized 57 clofarabine 57 Plicera 57 Proxinium TM 57 alvimopan 57 multicenter randomized 57 INCB# [001] 57 Clolar ® 57 RG# [001] 57 JAK inhibitor 57 tolerability 57 treatment naïve genotype 57 Phase III confirmatory 57 tesmilifene 57 Marketing Authorization Application MAA 57 T DM1 57 metastatic sarcomas 57 Inc. Nasdaq VVUS 57 tanespimycin 57 unique alkylating agent 57 custirsen 57 ARDIS 57 VEGF Trap 57 REOLYSIN ® 57 tesetaxel 57 Panzem R NCD 57 LibiGel Phase III 57 elotuzumab 57 teduglutide 57 Phase 1b clinical trials 57 Phase #/#a trial 57 sodium Injection 57 JZP 57 pivotal bioequivalence 57 dextromethorphan quinidine 57 clinical trials 57 GetGoal Phase III 57 Allovectin 7 57 Phase Ib IIa 57 mGluR5 negative 57 teriflunomide 57 Genasense ® 57 HuMax EGFr 57 Genz # 57 CONSERV 57 CR# vcMMAE 57 satraplatin Phase 57 multicentre randomized double 57 Exherin TM 57 brivaracetam 56 Drug Eluting Stent System 56 Phase #b/#a trial 56 monotherapy 56 prospective randomized controlled 56 SinuNase 56 Genasense ® oblimersen 56 Augment Injectable 56 New Drug Application 56 ascending doses 56 Pirfenidone 56 Elagolix 56 picoplatin 56 Tanespimycin 56 MEK inhibitor RDEA# 56 NP2 Enkephalin 56 ENDEAVOR IV 56 ThermoDox R 56 Phase IIb kidney transplant 56 Phase III Clinical Trials 56 pralatrexate 56 AVADO 56 satraplatin 56 ozarelix 56 single ascending dose 56 PLK1 SNALP 56 Allovectin 7 ® 56 Perifosine 56 pharmacokinetic PK 56 huC# DM4 56 PSN# [002] 56 PS# [001] 56 SPIRIT III 56 AzaSite Plus 56 CoFactor 56 prospective multicenter 56 Phase III multicenter 56 Azedra 56 Anturol 56 pharmacokinetics PK 56 trastuzumab DM1 T DM1 56 Ceplene 56 GATTEX ® 56 HGS# 56 mipomersen 56 initiate Phase IIb 56 PEG Interferon lambda 56 APF# Phase 56 sunitinib malate 56 carfilzomib 56 MERLIN TIMI 56 belinostat 56 Allovectin 7 R 56 Alpharadin 56 blinded randomized placebo controlled 56 subcutaneous formulation 56 metastatic castrate resistant 56 QNEXA 56 talactoferrin 56 platinum refractory 56 Cloretazine ® 56 Testosterone MDTS ® 56 pharmacodynamics 56 dose dose escalation 56 controlled multicenter 56 ofatumumab HuMax CD# 56 GLP toxicology studies 56 multicentre 56 TASKi2 56 oral formulation 56 preclinical 56 blinatumomab 56 Bezielle 56 IIa clinical trial 56 sNDA submission 56 EDEMA4 56 oral sapacitabine 56 TLK# 56 TELINTRA 56 evaluating Xcytrin 56 BLA submission 56 cetrorelix 56 Diabetic Macular Edema 56 OncoVEX GM CSF 56 investigational compounds 56 Fibrillex TM 56 Fx #A 56 TMC# [002] 56 Nasdaq MAPP 56 EDEMA3 56 LEVADEX 56 MEND CABG 56 cutaneous T cell 56 eniluracil 56 MGCD# [001] 56 OvaRex ® MAb 55 R#/MEM # 55 MINDSET 55 NDA submission 55 Randomized Phase II 55 GEM OS1 55 RIBBON 55 MBP# [001] 55 Sapacitabine 55 blind multicenter 55 ALN VSP Phase 55 afatinib 55 randomized multicenter Phase III 55 initiated Phase Ib 55 ruxolitinib 55 Prostate AdenoCarcinoma Treatment 55 denufosol 55 Azixa 55 Biologics License Application BLA 55 Ophena TM 55 Hsp# inhibitor 55 evaluating carfilzomib 55 unblind 55 Phase III Clinical Trial 55 virus HCV protease inhibitor 55 aflibercept 55 evaluating T DM1 55 randomized controlled clinical 55 leading oral taxane 55 pharmacokinetic studies 55 HCD# [002] 55 Phenoptin 55 PROVENGE sipuleucel T 55 Dual Opioid 55 confirmatory Phase 55 myelofibrosis 55 JAK1 55 relapsing remitting multiple sclerosis 55 torezolid phosphate 55 Androxal TM 55 metastatic CRPC 55 acyclovir Lauriad R 55 eculizumab 55 evaluating REVLIMID 55 QLT# 55 MIST II 55 Vicinium TM 55 BAY #-# 55 L BLP# 55 ACTEMRA 55 hypoxia activated prodrug 55 prGCD 55 relapsing multiple sclerosis 55 refractory AML 55 assessing T DM1 55 Corlux 55 blinded placebo controlled 55 PRECISE trial 55 KRN# 55 NGX# 55 XL# [003] 55 prospective multicenter randomized 55 interferon gamma 1b 55 XIENCE V Stent System 55 BLOOM DM 55 Pivotal Study 55 investigational oral 55 metastatic castration resistant 55 multicentre randomized 55 SPIRIT FIRST 55 Combination REOLYSIN R 55 rALLy trial 55 safety tolerability pharmacokinetics 55 HspE7 55 Second Pivotal Phase 55 PF # [001] 55 including eniluracil ADH 55 multicenter randomized controlled 55 Serada 55 Annamycin 55 refractory multiple myeloma 55 palifosfamide 55 Bronchitol 55 brentuximab vedotin SGN 55 tivozanib 55 SYMMETRY trial 55 COSIRA trial 55 NEO3 55 dirucotide MBP# 55 phase III ACCLAIM 55 LibiGel testosterone gel 55 rNAPc2 55 secondary efficacy endpoints 55 PANVAC VF 55 docetaxel chemotherapy 55 AQ4N 55 Phase III ALLEGRO 55 INCB# [002] 55 L MTP PE 55 Aflibercept 55 IMA# 55 CHAMPION PCI 55 randomized clinical 55 TAXUS Element Stent System 55 lomitapide 55 EVEREST II 55 sodium thiosulfate STS 55 neratinib 55 Urocidin 55 OPT CHF 55 Zenvia ™ 55 investigational monoclonal antibody 55 safety tolerability 55 ATTRACT 55 Viramidine 55 ACTEMRA TM 55 evaluable patients 55 BLA filing 55 HGS ETR2 55 pralatrexate injection 55 opioid induced bowel dysfunction 55 FavId 55 TRISENOX 55 PXD# 55 TG MV 55 clinical pharmacology studies 55 PROVENGE ® 55 metastatic colorectal cancer 55 dacetuzumab SGN 55 OLpur TM H2H 55 investigational 55 CEQ# 55 Archexin 55 THALOMID 55 antibody MAb 55 stated Michelle Berrey 55 ThermoDox 55 methylnaltrexone 55 ToGA 54 PRIMO CABG 54 Genasense 54 ADVEXIN 54 RSD# iv 54 CLIRS trial 54 unblinding 54 microplasmin 54 refractory Hodgkin lymphoma 54 Board DSMB 54 Marketing Authorization Application 54 ORENCIA ® 54 VELCADE 54 dependent kinase inhibitor 54 XL# SAR# 54 elagolix 54 investigational humanized monoclonal antibody 54 OPAXIO 54 Inc. Nasdaq ALTH 54 Chemophase 54 active comparator 54 Zybrestat 54 ASA# 54 budesonide MMX 54 Troxatyl 54 ERBITUX 54 injectable enzyme 54 painful diabetic neuropathy 54 CLARITY study 54 elacytarabine 54 Androxal 54 AEGR 54 refractory metastatic colorectal cancer 54 mitogen activated ERK kinase 54 REVLIMID lenalidomide 54 Biologics License Application 54 seliciclib CYC# 54 fostamatinib 54 Clolar 54 BCX# 54 BiTE R 54 diabetic neuropathic pain 54 2 methoxyestradiol 54 BCIRG 54 Nasdaq PGNX today 54 Atiprimod 54 Omacetaxine 54 Ceflatonin 54 IMC #B 54 castrate resistant prostate cancer 54 IL# PE#QQR 54 varespladib 54 ENDEAVOR III 54 AZX# 54 histone deacetylase HDAC inhibitor 54 Aurexis 54 OAB overactive bladder 54 nimotuzumab 54 velafermin 54 IRX 2 54 Carfilzomib 54 anticancer compound 54 Locteron ® 54 TBC# 54 Luveniq 54 PROPEL 54 IIb clinical trial 54 Ceflatonin R 54 fidaxomicin Phase 3 54 Imprime PGG 54 PIX# [002] 54 GOUT 54 IND enabling 54 randomized multicentre 54 EXPAREL ™ 54 oral prodrug 54 IMPACT DCM 54 Fodosine 54 CYT# 54 AIMM trial 54 Cloretazine 54 ProLindac 54 alogliptin 54 adecatumumab 54 dosing regimens 54 diarrhea predominant irritable 54 NEBIDO 54 BEMA Buprenorphine 54 PREOS 54 tolevamer 54 PIX# trial 54 myelodysplastic syndromes MDS 54 LEP ETU 54 BENLYSTA ™ 54 TEMSO 54 prospective randomized placebo 54 lymphoma CTCL 54 refractory CLL 54 ixabepilone 54 double blinded randomized 54 Traficet EN 54 evaluating Actimmune 54 visilizumab 54 DASISION 54 LUMINATE 54 AIR CF1 54 Efficacy Results 54 PREVAIL 54 systemic Phase 1b 54 trastuzumab emtansine T DM1 54 Phase III VISTA 54 Initiates Phase 54 dosing cohort 54 candidate AQ4N 54 omacetaxine mepesuccinate 54 lubiprostone 54 MoxDuo IR 54 Bicifadine 54 PSMA ADC 54 Ventavis 54 MLN# 54 Ixempra 54 Alzhemed TM 54 Quinamed 54 Brentuximab Vedotin SGN 54 HRPC 54 NSCLC 54 APF# 54 oritavancin 54 Anturol TM 54 Ceflatonin ® 54 HuMax CD4 54 Celacade TM technology 54 Genasense R oblimersen 54 QNEXA ® 54 sBLA 54 LBH# 54 AeroLEF 54 confirmatory clinical 54 Phase IIB clinical 54 initiate Phase Ib 54 PRECISE 54 Asentar 54 pediatric glioma 54 Phase 2b Clinical Trial 54 Maximum Tolerated Dose MTD 54 PEG SN# 54 CA4P 54 naproxcinod 54 NUVIGIL 54 vosaroxin 54 CORLUX 54 ILUVIEN ® 54 PROMACTA 53 zalutumumab 53 DR Cysteamine 53 Anturol ® 53 nitazoxanide 53 tolerated dose MTD 53 Diabetic Macular Edema DME 53 HCV RESPOND 2 53 PI3K/Akt pathway inhibitor 53 ecallantide 53 Personalized Immunotherapy 53 MIVI III 53 systemic ALCL 53 imetelstat GRN#L 53 initiate Phase 1b 53 Aryplase 53 Sym# 53 Phase 2b monotherapy 53 castration resistant prostate cancer 53 CB2 selective receptor agonist 53 LymphoStat B Phase 53 pertuzumab 53 ponatinib 53 dalbavancin 53 cell lymphoma CTCL 53 LibiGel ® 53 TOCOSOL Paclitaxel 53 apaziquone 53 refractory gout 53 perifosine KRX 53 Xibrom QD 53 3 registrational trial 53 Alocrest 53 Panzem R 53 Phase Ia Ib 53 brain metastases originating 53 Cladribine Tablets 53 GRN#L 53 oral mucositis 53 liposomal formulation 53 bosentan 53 Phase III metastatic melanoma 53 Microplasmin 53 NASDAQ CXSP announced 53 ALSYMPCA 53 generation purine nucleoside 53 registrational Phase 53 Soliris TM eculizumab 53 PEGylated interferon beta 1a 53 trial evaluating PRX# 53 evaluating Vectibix 53 T Pred 53 Phase III psoriasis 53 LymphoStat B TM 53 Ocrelizumab 53 PHX# 53 trastuzumab Herceptin R 53 GEM OS2 53 enzastaurin 53 novel histone deacetylase 53 Serdaxin ® 53 Onalta ™ 53 preclinical efficacy 53 Hyphanox 53 reslizumab 53 sorafenib tablets 53 placebo controlled clinical trials 53 TRO# 53 Application BLA 53 Dapagliflozin 53 RADIANT 53 cancer neuroendocrine tumor 53 evaluating tivozanib 53 cutaneous T 53 Nasdaq OPTR 53 R roscovitine CDK cyclin 53 GATTEX 53 Æterna Zentaris 53 Successfully Completes Phase 53 GATTEX TM 53 LymphoStat B belimumab 53 IIa clinical 53 PrevOnco 53 DSMB 53 Nasdaq NYMX 53 Tesetaxel 53 PrevOnco ™ 53 COU AA 53 IDX# 53 Tarvacin TM 53 AMR# 53 Xcytrin R 53 IND submission 53 Rebif ® 53 controlled multicenter Phase 53 GVAX immunotherapy 53 panitumumab 53 YONDELIS 53 Phase IIb Clinical Trial 53 telaprevir dosing 53 Investigational Device Exemption 53 dose regimens 53 lumiliximab 53 ABL inhibitor 53 Phase IIb Trial 53 immunosuppressive compound 53 humanized anti 53 ocrelizumab 53 pharmacokinetics 53 albinterferon alfa 2b 53 Matrix Phase 2b 53 Azedra TM 53 crizotinib PF # 53 Tarceva TM 53 M Vax 53 romidepsin 53 forodesine HCl 53 PRNewswire FirstCall Genta Incorporated 53 palifosfamide Zymafos TM 53 Nasdaq ALTH 53 TACI Ig 53 LEUKINE 53 immunotherapeutic agent 53 ZEVALIN 53 Topical Interferon Alpha 2b 53 label multicenter randomized 53 metastatic HRPC 53 TRANSFORMS 53 brentuximab vedotin 53 fosbretabulin 53 ridaforolimus 53 EMPOWER ™ 53 trodusquemine 53 pomalidomide 53 Pivotal Phase II 53 multicenter placebo controlled 53 Completes Patient Enrollment 53 Inhalation Solution 53 novel VDA molecule 53 bicifadine 53 topical formulation 53 refractory cutaneous T 53 BST CarGel R 53 MOTIVATE 53 Icatibant 53 randomized 53 Phase III Trial 53 Dr. Fahar Merchant 53 ACCORD COPD 53 Xcytrin 53 azficel T 53 MDV# 53 SABCS 53 Raptiva ® 53 MAGE A3 ASCI 53 Spiro Rombotis President 53 Zenvia 53 Cytokinetics Incorporated NASDAQ CYTK 53 LEVADEX ™ 53 II Clinical Trial 53 PREOS R 53 EmbraceAC 53 vicriviroc 53 Androxal ® 53 Zelrix 53 Onrigin 53 Nexavar ® 53 AZILECT R 52 velafermin belinostat 52 pseudobulbar affect PBA 52 Veronate 52 MKC# MT 52 pixantrone 52 oral rivaroxaban 52 oral taxane 52 investigational hepatitis C 52 voclosporin 52 Taxotere ® 52 INSPIRE Trial Phase III 52 Ozarelix 52 drug pipeline TAFA# 52 Albuferon Phase 52 ARIKACE 52 AIR CF2 52 EOquin TM phase 52 Hematide TM 52 Phase lll 52 Q#IR 52 avanafil 52 lorvotuzumab mertansine 52 Shigamabs ® 52 bile duct tumor 52 vidofludimus 52 EVIZON 52 ORMD 52 Phase IIIb study 52 vandetanib 52 sNDA 52 dose escalation phase 52 catheter occlusion 52 GRAVITAS trial 52 TORISEL 52 SCH # 52 Trial Evaluating 52 recurrent malignant glioma 52 Multiple Ascending Dose 52 velaglucerase alfa 52 Nasdaq ISTA 52 tolerability profile 52 Ofatumumab 52 valopicitabine 52 DSMB recommended 52 histamine dihydrochloride 52 Xeloda ® 52 dasatinib Sprycel ® 52 initiate Phase 2b 52 Lymphoseek ® 52 VNP#M 52 ENRICH trial 52 PRNewswire FirstCall ISTA Pharmaceuticals 52 NPSP# 52 Civacir 52 multicenter multinational 52 Xcellerated T Cells 52 NOXAFIL 52 zanolimumab 52 PRECISE Trial 52 PEGINTRON TM 52 LibiGel 52 Feraheme 52 Cimzia ® 52 ELND# 52 Dacogen 52 subcutaneously administered 52 prospective observational 52 UPLYSO 52 VALOR trial 52 rindopepimut 52 Cotara 52 RSD# oral 52 icatibant 52 Adlea 52 Cloretazine R 52 ancrod 52 eltrombopag 52 blind placebo 52 recurrent glioblastoma 52 Phase 2a clinical trials 52 RELOVAIR ™ 52 PRTX 52 aclidinium bromide 52 initiate multicenter 52 CRx 52 low dose cytarabine 52 Urocortin 2 52 severe hypercholesterolemia 52 pharmacodynamic 52 trastuzumab DM1 52 StemEx 52 Genasense oblimersen sodium Injection 52 intravenous formulation 52 APEX AMI trial 52 ADX# 52 nalbuphine ER 52 AZILECT ® 52 PNP inhibitor 52 MBP# dirucotide 52 Chrysalin 52 BiovaxID TM 52 AeroLEF TM 52 Diamyd ® 52 Xanafide 52 PRIMO CABG2 52 Taxotere R 52 TAXUS ATLAS 52 MONOVISC 52 refractory chronic lymphocytic 52 efficacy endpoint 52 LE SN# 52 sorafenib Nexavar ® 52 thorough QT 52 evaluating RDEA# 52 radiation sensitizer 52 compound INCB# 52 efficacy endpoints 52 MyVax R 52 SILENOR TM 52 plus dexamethasone 52 Phase III ThermoDox 52 midstage trials 52 primary endpoint 52 non metastatic osteosarcoma 52 Glufosfamide 52 placebo controlled dose escalation 52 mapatumumab 52 cannabinor 52 preclinical studies 52 Confirmatory Phase 52 New Drug IND 52 miconazole Lauriad R 52 Ophena 52 Clonicel 52 telaprevir dosed 52 tamibarotene 52 Targretin 52 humanized monoclonal antibody 52 hematologic malignancies 52 Proellex TM 52 evaluating satraplatin 52 paclitaxel poliglumex 52 blinded randomized 52 randomized controlled multicenter 52 HepeX B TM 52 sodium glucose cotransporter 52 Bepreve 52 vinorelbine 52 evaluating bafetinib 52 nonclinical studies 52 EndoTAG TM -1 52 ADAGIO study 52 Ostarine 52 JANUVIA 52 isavuconazole 52 PHASE III 52 HoFH 52 RCW breast cancer 52 Prospective Randomized 52 Denufosol 52 ZYBRESTAT TM 52 Telavancin 52 otelixizumab 52 mesylate tablets 52 relapsed refractory 52 proprietary transdermal patch 52 efficacy 52 Hsp# Inhibitor 52 daclizumab 52 acyclovir Lauriad ® 52 maribavir 52 ospemifene 52 Serdaxin 52 Daclizumab 52 LUVENIQ 52 Premarket Approval PMA 52 Commence Phase 52 telomerase inhibitor drug 52 severe oral mucositis 52 Dyloject TM